Prognostic factors in metastatic colorectal cancer in Tunisia: a retrospective study of 130 patients

##plugins.themes.academic_pro.article.sidebar##

Published Mar 25, 2015
Download
pdf
Vol. 93 No. 1 (2015): Issue Jan 2015

##plugins.themes.academic_pro.article.main##

Masmoudi Safia
Khanfir Afef

Abstract

Background: The survival of patients with a metastatic colon cancer has improved with palliative chemotherapy, targeted therapies and surgery. Several prognostic factors influencing the survival of these patients were identified in the literature represented mainly by clinical factors: general condition, number and site of metastases, rate of white blood cells, initial carcinoembryonic antigen (CEA) rate, hemoglobin level, and therapeutic factors mainly represented by resection of metastases.

Aim: To evaluate within a Tunisian retrospective study the significant prognostic factors on survival of metastatic colorectal cancer (MCRC).

Methods : We collected retrospectively 130 patients with MCRC treated in Sfax from january 2000 to December 2007. Uni and multivariate analysis were performed according to cox model for the following factors : Age or > 40 years, gender, synchronous vs metachronous metastases, disease-free survival (DFI) 1 > 1year, tumor site(colon vs rectum), performance status or PS ( 0-1or 2-3), white blood cells count (< or > 103/ml3 , haemoglobin rate (Hb) or > 11g/dl, seric carcinoembryonic antigen rate (CEA) < vs > 10 ng/ml, number of metastatic sites (single vs multiple), site of metastatic site (liver vs extrahepatic) and resection or not of the metastatic localizations. Results: Statistical analysis showed for univariate analysis the positive impact of : PS 1, (Hb) rate > 11 g/dl, CEA) < 10 ng/ml and resection of metastases, while in in multivariate analysis, they were : a good PS and Hb > 11 g/dl.

Conclusion: Our retrospective study confirmed the known prognostic impact of simple clinical tools like a good performance Status and Hb > 11 g/dl, a (CEA) rate lower than 10 ng/ml and resection of metastases which were identified by several other series such as predictive factors of a better survival in patients with metastatic colorectal cancer.

Keywords:

Colorectal cancer; Metastasis; Prognostic factors; Surviva

##plugins.themes.academic_pro.article.details##

References

  1. Faivre J, Manfredi S, Bouvier AM. Epidemiology of colorectal cancer liver metastases. Bull Acad Natl Med 2004;187:815-23
  2. De Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first line treatment in advanced colorectal cancer. J Clin Oncol, 2000; 18: 2938-47.
  3. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004; 240: 644-658
  4. Bartlett DL, Chu E. Can metastatic colorectal cancer be cured? Oncology (Williston Park). 2012;26:266-75.
  5. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355:1041-7
  6. Köhne CH, van Cutsem E, Wils J, et al. Phase III study of weekly highdose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 2005; 23: 4856-65
  7. Saltz LB, Cox JV, Blanke C, et al. For the Irinotecan Study Group. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000; 343: 905-14.
  8. Perez N, Tournigand C, Mabro M, et al. Survie à long terme des cancers colorectaux métastatiques sous chimiothérapie par 5-fluoro-uracile. Rev Med Interne 2004;25:124-128.
  9. Pop D, Venissac N, Leo F, Karimdjee BS, Lopez S, Mouroux J. Surgical treatment of pulmonary metastases of colorectal cancer. Do the indications evolved? Ann Chir. 2004; 129: 589-95
  10. Rougier P, Milan C, Lazorthes F, et al. Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer. Fondation Française de Cancérologie Digestive. Br J Surg 1995;82:1397-400
  11. Ng SL, Burns WI, Snyder RD, et al. A retrospective cohort study of metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy, with an exploratory analysis of changing serum carcinoembryonic antigen levels. Asia Pac J Clin Oncol. 2012;8:172-9
  12. Gharbi O, Chabchoub I, Limam S et al. Facteurs pronostiques et survie des cancers colorectaux métastatiques au CHU de Sousse (Tunisie): étude comparative de deux périodes de traitement de 200 patients. Bull Cancer 2010;97: 445-51
  13. Michel P, Roque I, Di Fiore F, et al. Colorectal cancer with non-resectable synchronous metastases: should the primary tumor be resected? Gastroenterol Clin Biol. 2004; 28:434-7
  14. Köhne CH, Cunningham D, Di CF, et al. Clinical determinants of survival in patients with 5-fluorouracil based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 2002;13: 308-17
  15. . Saltz LB, Douillard JY, Pirotta N, et al. Irinotecan plus fluorouracil/Leucovorin for metastatic colorectal cancer. A New Survival Standard. Oncologist 2001; 6: 81-91.
  16. Younes RN, Rogakto A, Brenmam.MF. The influence of intra-operative hypotension and perioperative blood transfusion on disease free survival in patients with complete resection of colorectal liver metastases. Ann Surg 1991; 214: 107-113
  17. Nordlinger B, Jaeck D, Gulguet M, Vaillant JC, Balladur P, Schaal JC. Résection chirurgicale des métastases hépatiques. Enquête de l'association française de chirurgie. In: Traitement des métastases hépatiques des cancers colorectaux. Springer-Verlag 1992; 141-159
  18. Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal metastases to the liver. A prognostic scoring system to improve case selection based on 1568 patients. Cancer 1996;77:1254-62
  19. Sugihara K , Hojo K, Moriya Y, Yamasaki S, Kosuge T, Takayama T. Pattern of recurrence after hepatic resection for colorectal metastases. Br J Surg 1993; 80:1032-5
  20. Scheele J, Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg 1995; 19: 59-71.
  21. Beckurts KTE, Hölscher AH, Thorban St, Bollschweiler E, Siewert JR. Significance of lymph node involvement at the hepatic hilum in the resection of colorectal liver metastases. Br J Surg 1997; 84: 1081-1084
  22. Van Ooijen B, Wiggers T, Meijer S, et al. Hepatic resections for colorectal metastases in the Netherlands. A multi institutional 10-year study. Cancer 1992; 70: 28-34.
  23. Castaing D, Vinet E. Les clampages en chirurgie hépatiques. J Chir 2002; 139 :77-84
  24. Yamamoto J, Shimada K, Kosuge T, Yamasaki S, Sakamoto M, Fukuda H. Factors influencing survival of patients undergoing hepatectomy for colorectal metastases. Br J Surg 1999; 86: 332-337
  25. Ekberg H, Tranberg KG, Andersson R, et al. Determinants of survival in liver resection for colorectal secondaries. Br J Surg 1986;73:727-31
  26. Butler J, Attiyeh FF, Daly JM. Hepatic resection for metastases of the colon and rectum. Surg Gynecol Obstet 1986; 162 : 109-113.
  27. Fortner JG, Silva JS, Golbey RB, Cox EB, Maclean BJ. Multivariate analysis of a personal series of 247 consecutive patients with liver metastases from colorectal cancer. Ann Surg. 1984; 199: 306-316
  28. Elias D, Cavalcanti A, Sabourin JC, Pignon JP, Ducreux M, Lasser PH. Results of 136 curative hepatectomies with a safety margin of less than 10 mm for colorectal metastases. J Surg Oncol 1998 ; 69 : 88-93.
  29. McAfee MK, Allen MS, Trastek VF, Ilstrup DM, Deschamps C, Pairolero PC. Colorectal lung metastases: results of surgical excision. Ann Thorac Surg 1992; 53: 780-5.
  30. Pfannschmidt J, Muley T, Hoffmann H, Dienemann H. Prognostic factors and survival after complete resection of pulmonary metastases from colorectal carcinoma: experiences in 167 patients. J Thorac. Cardiovasc Surg 2003; 126: 732-9.
  31. Regnard JF, Grunenwald D, Spaggiari L, et al. Surgical treatment of hepatic and pulmonary metastases from colorectal cancers. Ann Thorac Surg 1998; 66: 214-9.
  32. Saito Y, Omiya H, Kohno K, et al. Pulmonary metastasectomy for 165 patients with colorectal carcinoma: a prognostic assessment. J Thorac Cardiovasc Surg 2002; 124: 1007-13.